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ABSTRACT
Introduction: Little is known about the epide-
miology, causes and outcomes of neonatal 
cholestasis in the Asian population beyond Japan 
and Taiwan.
Methods: This was a prospective, observational 
study on patients with neonatal cholestasis who 
were referred to the University of Malaya Medical 
Centre, Malaysia, between November 1996 and 
May 2004. 
Results: Biliary atresia (BA) (29 percent) and idio-
pathic neonatal hepatitis (38 percent) were the 
two commonest causes of neonatal cholestasis (n 
is 146) that were referred. Out of the 39 patients 
(27 percent of the total) who died at the time of 
review,  35 succumbed to end-stage liver disease. 
Three of the four patients (three BA, one progress-
ive familial intrahepatic cholestasis [PFIC]) who 
had a living-related liver transplant (LT) died 
after the surgery (two BA, one PFIC). Six (four 
percent) of the remaining 107 survivors had liver 
cirrhosis. The overall four-year survival rates for 
patients with native liver and LT as well as those 
with native liver alone for all cases of neonatal 
cholestasis were 72 percent and 73 percent, 
respectively, while the respective survival rates 
for BA were 38 percent and 36 percent. 
Conclusion: BA and idiopathic neonatal hepatitis 
are important causes of neonatal cholestasis in 
Malaysian infants. In Malaysia, the survival rate of 
patients with neonatal cholestasis, especially BA, 
is adversely affected by the lack of a timely LT. 
Keywords: liver transplant, neonatal cholestasis, 
outcome
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INTRODUCTION
The causes of neonatal cholestasis are manifold.(1,2) 
Biliary atresia (BA) is the most commonly recognised 
cause of neonatal cholestasis throughout the world.(3-6) 
Other causes vary depending on the population studied. 
Among Caucasians, the three most common causes of 
neonatal cholestasis are BA, idiopathic neonatal hepatitis 
(INH) and alpha-1 antitrypsin (α1AT) deficiency.(3) 
Among Asians, α1AT deficiency is uncommon,(7-9) while 
citrin deficiency has recently been found to be a common 
cause of neonatal cholestasis with hepatic steatosis.(10,11)
 Liver transplantation (LT) is the standard treatment 
for end-stage liver failure and fulminant liver failure in 
children.(12,13) In Europe and the United States, the results 
of paediatric LT have been excellent, with the majority 
of the liver grafts obtained from cadaveric donors.(12,13) 
In Asia, a severe lack of cadaveric grafts is a major 
problem that is faced throughout the region.(14) In order 
to overcome this problem, living-donor LT has been 
established in Japan, Taiwan, Hong Kong and Korea.(14)
 LT is limited in Malaysia. It has only been made 
available in one private medical centre since 1995 and 
in one government hospital since 2002.(15) By the end of 
2005, a total of 80 Malaysians had gone through an LT,(15) 
and out of these, only 16% had received their grafts from 
cadaveric donors.(15) The overall one-year survival rate 
was 69%.(15) Little is known about the epidemiology and 
outcomes of neonatal cholestasis in the Asian population 
beyond Japan and Taiwan. The objectives of the present 
study were to ascertain the epidemiology, the short-to-
medium-term outcomes and the effect of limited LT on 
neonatal cholestasis in a single institution in Malaysia. 
 
METHODS 
This was a prospective, descriptive, non-interventional 
study conducted at the Department of Paediatrics, 
University of Malaya Medical Centre (UMMC), Kuala 
Lumpur, Malaysia. Infants with neonatal cholestasis who 
were referred to the department over the course of 7.5 
years, between November 1996 and May 2004, were 
selected and studied. The inclusion criteria were infants 
born to Malaysian citizens, where adequate follow-up 
information was available for at least a period of four 
years and where a known final outcome was available. 
The present study was approved by the ethics committee 
of UMMC.
 All patients with neonatal cholestasis were investigated 
according to a systematic protocol, which included a 
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detailed history and physical examination, haematologi-
cal, biochemical and serological investigations, imaging 
studies and percutaneous liver biopsy, where appropriate.(6) 
An operative cholangiography was performed if the 
outcome of the investigations was inconclusive and if 
BA was clinically suspected. A final diagnosis of neonatal 
cholestasis was made after careful consideration of all the 
available data.  
 Neonatal cholestasis was defined as the onset of 
clinically apparent jaundice within the first four months 
of life, with a conjugated bilirubin level > 17 µmol/L 
(1 mg/dL) if the total bilirubin level was < 85 µmol/L 
(5 mg/dL), or a conjugated bilirubin level > 20% of 
the total bilirubin level if the total bilirubin level was 
> 85 µmol/L.(16) BA was diagnosed based on the criteria 
identified by McKiernan et al(17) and Fischler et al,(18) 
when other causes of neonatal cholestasis were excluded 
and confirmation was obtained at laparotomy with an 
operative cholangiogram.(17,18) BA was considered to be 
definitive when laparotomy confirmed the obliteration 
of extrahepatic bile ducts, and presumptive when there 
was a consistent clinical feature and a natural course 
of progressive jaundice, eventual liver cirrhosis and 
death due to liver failure, but without confirmation by 
operative cholangiogram.
 The diagnosis of progressive familial intrahepatic 
cholestasis (PFIC) was based on the presence of the 
following features: chronic unremitting cholestasis with 
onset in infancy, the exclusion of anatomic and metabolic 
aetiologies, raised levels of conjugated bilirubin and 
alkaline phosphatase and low to normal levels of serum 
gamma-glutamyl transferase (γGT).(19) A positive family 
history was necessary if γGT was not low.(20) α1AT 
deficiency was diagnosed by performing serum α1AT 
levels and phenotypes. An infant was considered to have 
INH after a thorough history, physical examination and 
Underlying cause No. (%) Alive with minor or Alive with major Died  
    no residual morbidity  morbidity* 
Bile duct obstruction  
 Biliary atresia   42 (29) 14a   3  25 
  Definite (n = 35, 24%)
  Presumptive (n = 7, 5%)
 Choledochal cyst   1 (0.7)  1 
 Alagille syndrome   1 (0.7)    1 
 Caroli disease   1 (0.7)      1 
 Inspissated bile syndrome   1 (0.7)  1 
Neonatal hepatitis 
 Idiopathic 
  Idiopathic neonatal hepatitis  56 (38) 52   3   1 
 Viral  
  Cytomegalovirus  13 (9) 12     1 
  Herpes simplex virus    2 (1.5)  2 
 Bacterial 
  Urinary tract infection   3 (2)  3 
Cholestatic syndromes  
 PFIC   5 (4)    1   4 
Endocrine   
 Congenital adrenal hyperplasia   1 (0.7)  1 
 Congenital hypothyroidism   3 (2)  3 
 Congenital hypopituitarism   1 (0.7)  1 
Metabolic  
 Galactosaemia   1 (0.7)  1 
Neonatal haemachromatosis   2 (1.5)      2 
 Acute liver failure, undefined    4 (3)  1     3 
Toxic    
 TPN-associated cholestasis   7 (5)  7 
Miscellaneous  
 Perinatal asphyxia   2 (1.5)    2 
Total (%)  146 (100) 99 (68) 10 (7) 37 (25)
* The overall mortality rate of patients who presented with acute liver failure was 83% (5 out of 6). 
a Includes two patients who survived after successful liver transplantation.
TPN: total parenteral nutrition; PFIC: progressive familial intrahepatic cholestasis
Table I.  Aetiology and outcomes of liver disease in 146 infants with neonatal cholestasis.
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laboratory evaluations failed to identify the underlying 
cause of the neonatal cholestasis.(21) 
 A minimum of 48 months of follow-up data was 
available for all the patients. The age of death (months) 
for patients who died was noted. The outcomes of 
patients that were still alive were determined based 
on their clinical reviews. Basic clinical information, 
including growth parameters, general health, the 
presence of liver cirrhosis and its complications, daily 
and school activities, were noted. For patients who 
were still being followed up, the clinic entries nearest 
to June 2007, i.e. 48 months after the close of the study, 
were noted. For patients who had been discharged from 
the follow-up clinic, their latest clinical information 
was obtained from the care providers via telephonic 
interview.
 The outcome measures were divided into the 
following: survival with or without minimal morbidity, 
survival with major morbidity and death. Major morbidity 
was defined as the presence of any of the following 
features: poor general health; major restrictions to 
lifestyle, including school activities; failure to thrive 
(minus two standard deviations for weight-for-age); the 
presence of liver cirrhosis or its complications and the 
need for LT. The Kasai procedure was considered to be 
successful if it resulted in the restoration of bile flow 
and normalisation of serum bilirubins (< 20 µmol/L) at 
any time.(17)
 The data was entered using the Statistical Package 
for the Social Sciences version 11.0 (SPSS Inc, Chicago, 
IL, USA) for Windows XP. The data was quoted as 
the median and range. Chi-square tests were used for 
categorical data, while Student’s t-test was used for a 
comparison of the numerical data.
 
RESULTS 
During the study period, a total of 154 patients with 
neonatal cholestasis were referred to the department for 
further evaluation. Eight patients were excluded: the 
parents of two patients were non-Malaysian citizens with 
no outcome data, while another six patients had either 
incomplete investigations or inadequate follow-up. 
Hence, the remaining 146 patients were studied. 
 BA (n = 42, 29%; 35 definite, seven presumptive) 
was the commonest cause of neonatal cholestasis (Table 
I). Despite extensive investigations, the underlying cause 
of neonatal cholestasis could not be identified in 56 (38%) 
cases, and these were considered to have INH. Neonatal 
cholestasis and BA were mainly seen in term infants, with 
a median gestational age of 40 weeks for both neonatal 
cholestasis and BA. The median age of onset of jaundice 
for all the cases was seven (range 1–90) days, while the 
median age at referral was 58 (range 16–260) days. For 
BA, the median age of onset of jaundice was seven (range 
1–75) days, while the median age at first presentation was 
60 (range 16–260) days. 
 Six infants had Down syndrome (four for INH, one 
each for galactosaemia and congenital hypothyroidism). 
Table II. Morbidity and mortality in 146 patients with neonatal cholestasis.
Condition Morbidity (n = 9) Cause of death (n = 39)
Biliary atresia  Liver cirrhosis, n = 3 Without Kasai procedure, n = 12
  After unsuccessful Kasai procedure, no LT, n = 12
  After unsuccessful LT, n = 2
Idiopathic neonatal hepatitis Liver cirrhosis, portal hypertension, (Down syndrome): intractable heart failure due to 
      bleeding oesophageal varices; n = 1 large atrioventricular septal defect, n = 1
 Hypersplenism and thrombocytopaenia, n = 1  
 (Down syndrome) developed acute
 myeloid leukaemia, n = 1
Progressive familial intra-  Liver cirrhosis and liver failure, n = 4
hepatic cholestasis   Post-LT due to severe sepsis, n = 1
Acute neonatal liver failure (n = 6) Acute liver failure, n = 5
Cytomegalovirus hepatitis   Liver cirrhosis and liver failure, n = 1
Caroli disease   Liver cirrhosis and intractable sepsis, n = 1
Alagille syndrome  Liver cirrhosis, failure to thrive, n = 1
Perinatal asphyxia  Severe neurodevelopmental 
 disabilities, n = 2
LT: liver transplant
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One patient with INH who had microcephaly and anal 
atresia at birth was subsequently diagnosed to have 
Kabuki syndrome at four years of age. 
 All the patients had a minimum of 48 months follow-
up (Table II, Fig. 1). 39 (27% of the total) patients had 
died and 107 were still alive at the time of review in June 
2008. Of the four patients who had LT, one is still alive 
with a functioning graft. The overall four-year survival 
rate of patients with native liver and LT, as well as those 
with native liver for all cases of neonatal cholestasis, was 
72% and 73%, respectively.
 Nine (6%) of the 107 survivors had major morbidity 
(Table II). Six patients had liver cirrhosis, portal 
hypertension and hypersplenism. One patient with Down 
syndrome, whose jaundice subsided at four months of 
age, developed acute myeloid leukaemia at two years 
of age. The patient responded well to chemotherapy and 
is currently in remission. Two patients with perinatal 
asphyxia survived with full recovery of the cholestatic 
jaundice, but had severe neurodevelopmental  impairment. 
The remaining 98 (66%) patients survived with their 
native livers, with minimal or no morbidity. 48 of the 107 
survivors were discharged from follow-up (median age 
27 months, range 48–63 months). None had evidence of 
liver disease. 
 Of the 39 patients who succumbed (median age of 
death 14 months, range 1–51 months), the patient with 
Down syndrome and INH died of intractable heart 
failure, due to a large atrial septal defect unrelated to 
liver disease. Three of the four patients who had LT died 
after the LT. The remaining 35 patients died of end-stage 
liver disease. A total of six patients died acutely. Of these, 
five patients with acute neonatal liver failure (ANLF) 
died without LT (survival rate 17%). Another patient 
with PFIC died of a massive haemorrhage secondary to 
non-compliance of medical therapy. Of the five patients 
with PFIC, four patients who had both progressive liver 
cirrhosis and liver failure died without LT at 18, 22, 39 
and 51 months of age, respectively. One patient died due 
to post-LT complications. The overall survival rate for 
PFIC was 0%.
 Of the 42 patients with BA, all 12 patients who 
were referred late died without undergoing the Kasai 
procedure and LT (median age of death 15 months, 
range 6–18 months). Of the remaining 30 patients (71% 
of the 42 patients with BA) who underwent the Kasai 
procedure, 15 were unsuccessful (success rate for the 
Kasai procedure was 50%). Of these 15 patients, 12 died 
without LT (median age of death 15 months, range 8–25 
months). Three patients with BA who had an unsuccessful 
Kasai procedure had LT, and only one is still alive with a 
functioning graft. For patients with BA, the overall four-
year survival rate (native liver and LT, 16 out of 42) was 
38%, while the four-year survival rate with native liver 
was 36% (15 out of 42). 
 Generally, patients with INH (n = 56, one died, 
mortality rate 2%) had a favourable outcome (Table I). 
One of the 13 patients with cytomegalovirus hepatitis 
died at 38 months of age due to progressive liver cirrhosis. 
Five of the six patients with ANLF died acutely without 
Fig. 1 Outcomes of 146 patients with neonatal cholestasis.
146 patients
Death (n = 39, 26%) Survived with native liver and major 
morbidity (n = 9, 6%) (6 liver cirrhosis, 
2 severe neurological disabilities, 
1 AML at two years)
Survived with no morbidity 
(n = 98, 66%)
35 died of liver 
disease, no LT 
(5 ANLF, 30 liver 
cirrhosis)
1 died of heart 
failure at one year
3 died 
after LT
1 survived 
with LT
97 survived with 
native liver
LT: liver transplantation
AML: acute myeloid leukaemia 
ANLF: acute neonatal liver failure 107 survived at four-year follow-up.
Overall four-year survival rate: 73%
4 had LT, 1 survived: 
Survival with LT: 25%
106 survived with native liver 
at four-year follow-up. Four-year 
survival with native liver: 72%
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LT. 29 patients with chronic liver failure died without 
LT. The parents of all these patients were counselled 
about the need for LT. Of these, only five explored the 
feasibility of LT; however, LT was not performed due to 
a lack of suitable living related donors. The parents of the 
remaining 24 patients declined the offer of LT. The main 
reasons for the decline were the prohibitively high cost 
(prior to 2002) and the possibility of the eventual failure 
of LT.
 Of the four patients who had LT (three for BA, one 
for PFIC), all received a liver graft from a living-related 
donor (biological father or mother as donor, n = 2 each). 
The median age at LT was 15 (range 12–22) months. One 
patient who underwent an unsuccessful Kasai procedure 
died soon after LT due to a primary graft non-function. 
The second patient with PFIC died one week after LT due 
to severe sepsis. The third patient underwent LT for an 
unsuccessful Kasai procedure for BA and died three years 
after LT due to a chronic graft rejection. The remaining 
patient survived with functioning grafts ten years after 
LT. 
DISCUSSION
The present study was conducted at a tertiary referral 
centre in Malaysia. It is likely that the cases of neonatal 
cholestasis that are reported in the present study represent 
the most severe of the cases, or those who required urgent 
attention. Only a population-based prospective study can 
determine the population incidence of the various causes 
of neonatal cholestasis. 
 BA and INH are the two most common causes of 
neonatal cholestasis that have been noted in Malaysia.(22) 
The percentage of patients with BA in the present study 
(29%) is similar to the figure of 38% noted by Karnameedi 
and Lim in a retrospective study conducted in the same 
institution.(22) However, unlike the previous study where 
all the other causes of neonatal cholestasis besides BA 
were classified as neonatal hepatitis, the present study 
identified various other causes of neonatal cholestasis.
 The diagnosis of INH in the present study was 
certainly a diagnosis by default, as a diagnosis of INH is 
often made after excluding various infectious, metabolic, 
endocrine and anatomical causes of neonatal cholestasis.(23) 
In addition, the present study has also confirmed that 
α1AT deficiency-related liver disease is uncommon in the 
Malaysian population.(24,25) 
 The absence of LT adversely affects the outcomes of 
BA, ANLF and PFIC.(26-28) LT was mainly offered to chronic 
liver failure patients and not for ANLF. There is a severe 
lack of cadaveric liver grafts for the replacement of livers 
afflicted with end-stage liver failure, fulminant disease or 
inborn errors of metabolism.(14) This is particularly severe 
in Asian countries.(14) In the present study, 36 patients who 
died succumbed to liver failure. The limited availability 
of cadaveric donors for LT and the prohibitive cost of 
transplant surgery at a private centre in the early years 
of the study period were the main contributing factors to 
the high mortality rate observed in the present study. Only 
four patients underwent LT. Of the 36 patients who died, 
34 died without LT. Another seven patients who survived 
showed evidence of liver cirrhosis and may require LT in 
the near future. Public campaigns to increase the number 
of cadaveric donors should be intensified in order to 
increase the availability of cadaveric grafts. 
 The outcome of BA is dependent on the timing 
of the Kasai procedure, the associated anomalies and 
the experience of the centre.(29,30) While the outcome of 
surgery for BA in the present study is comparable to 
that found in other studies, the overall outcome of BA, 
including for those who had an unsuccessful surgery, is 
not encouraging. The actuarial two-year survival rate 
with native liver was 36%, while the two-year actuarial 
overall survival rate with LT was 40%. The 36% survival 
rate with native liver is much lower than that observed 
in the results from the King’s College Hospital study 
(five-year survival rate with native liver was 60%),(31) but 
comparable to figures from the French National Study 
(five-year survival rate with native liver was 32%),(30) as 
well as findings in Taiwan (five-year survival rate with 
native liver was 35%).(26) 
 The relatively unfavourable overall outcome for 
BA is mainly due to late referral for the appropriate 
investigations to be conducted.(32) The median age at 
referral for all cases of neonatal cholestasis was 58 days. 
We have previously argued that since there is a limited 
availability of LT in Malaysia, efforts to improve the 
outcome of BA should ideally address the issue of late 
referral.(32,33) Efforts should be made to increase awareness 
of the potentially serious nature of cholestatic jaundice 
in infancy among all levels of healthcare staff.(32) Mass 
screening of BA by checking the patients’ stool colour, 
which has been conducted in Japan and Taiwan, should 
also be considered.(34,35)
 In conclusion, the present study showed that the two 
major causes of neonatal cholestasis in Malaysia are BA 
and INH. The absence of timely LT adversely affects 
the outcomes of patients with BA, ANLF and PFIC who 
develop end-stage liver disease.
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